Chemotherapy-related Cognitive Impairment and Acute Leukemia
NCT ID: NCT04644419
Last Updated: 2023-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
25 participants
OBSERVATIONAL
2020-11-03
2023-05-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
NCT05519579
Neurologic Morbidity and Disability in Acute Lymphoblastic Leukemia Survivors
NCT00664131
Study of Proteins in Promoting Chemotherapy Resistance in Samples From Patients With Acute Myeloid Leukemia
NCT01419496
Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia
NCT03441048
Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia
NCT00006097
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group of the LCCC1848
Patients in the control arm will receive standard of care.
none (observational study)
This is an observational study and does not include intervention delivery.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
none (observational study)
This is an observational study and does not include intervention delivery.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diagnosis of AML
* Receive 1) low-dose cytarabine or hypomethylating agent (HMA) in combination with Venetoclax chemotherapy OR 2) low-dose cytarabine or hypomethylating agent (HMA) in combination with Venetoclax chemotherapy and any investigational drugs
* have caregiver(s) willing to participate
* participate in the parent study (PACT study, NCT04570709)
* identified by patient as a caregiver
* ≥18 years of age
* speak and read English
Exclusion Criteria
\[Caregiver\]
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
American Cancer Society, Inc.
OTHER
UNC Lineberger Comprehensive Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ya-Ning Chan, MSN, RN
Role: PRINCIPAL_INVESTIGATOR
University of North Carolina, Chapel Hill
Ashley L Bryant, PhD, RN
Role: STUDY_CHAIR
University of North Carolina, Chapel Hill
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of North Carolina Lineberger Comprehenisive Cancer Center
Chapel Hill, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LCCC2045
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.